Table 1.
V gene usage of the cross-strain-reactive human monoclonal antibodies. The germline usage of the heavy and light chain variable genes was defined using the IMGT database.
| mAb | VH | DH | JH | aa mutations | VL | JL | aa mutations |
|---|---|---|---|---|---|---|---|
| 1C4a | 3-30⁎04 | 5-24⁎01 | 6⁎02 | 5/121 | 3-20⁎01 | 2⁎01 | 2/108 |
| 1C6 | 3-11⁎01 | 6-25⁎01 | 4⁎01 | 9/121 | 3-15⁎01 | 2⁎01 | 8/109 |
| 1D2 | 1-69⁎09 | 4-17⁎01 | 4⁎02 | 7/121 | 3-15⁎01 | 2⁎01 | 4/108 |
| 1E1a | 3-23⁎04 | 1-1⁎01 | 4⁎02 | 7/121 | 3-11⁎01 | 5⁎01 | 0/108 |
| 1F2a | 3-23⁎04 | 5-5⁎01 | 5⁎02 | 6/121 | 3-15⁎01 | 5⁎01 | 2/108 |
| 1F4a | 3-23⁎04 | 2-8⁎02 | 3⁎02 | 6/121 | 3-15⁎01 | 4⁎01 | 0/108 |
| 1G1a | 3-23⁎04 | 3-16⁎01 | 4⁎02 | 9/121 | 3-15⁎01 | 4⁎01 | 1/108 |
| 1G6 | 3-23⁎04 | 6-19⁎01 | 5⁎02 | 7/123 | 2D-40⁎01 | 4⁎01 | 3/108 |
| 3A4 | 3-33⁎01 | 5-24⁎01 | 3⁎02 | 6/127 | 3-15⁎01 | 3⁎01 | 3/108 |
| 3A6 | 1-69⁎09 | 3-22⁎01 | 4⁎02 | 5/125 | 3-11⁎01 | 1⁎01 | 2/108 |
| 3B6 | 1-69⁎09 | 5-24⁎01 | 4⁎02 | 5/121 | 3-11⁎01 | 1⁎01 | 6/108 |
| 3C4a | 1-69⁎09 | 1-7⁎01 | 4⁎02 | 4/121 | 3-20⁎01 | 2⁎01 | 7/108 |
| 3D2 | 4-34⁎01 | 3-9⁎01 | 4⁎02 | 0/127 | 3-15⁎01 | 1⁎01 | 0/108 |
| 3D3 | 1-69⁎09 | 3-9⁎01 | 4⁎02 | 4/121 | 3-11⁎01 | 2⁎01 | 1/108 |
| 3E1a | 4-4⁎07 | 3-16⁎02 | 4⁎02 | 4/121 | 1-5⁎03 | 1⁎01 | 0/108 |
| 3E2 | 1-3⁎01 | 3-9⁎01 | 4⁎02 | 1/127 | 3-15⁎01 | 4⁎01 | 3/108 |
| 5A2 | 4-59⁎01 | 1-1⁎01 | 4⁎02 | 3/123 | 4-1⁎01 | 2⁎01 | 4/110 |
| 5A4 | 3-23⁎04 | 3-3⁎01 | 6⁎02 | 5/128 | 1-9⁎01 | 3⁎01 | 1/110 |
| 5A6 | 3-30⁎14 | 2-8⁎02 | 4⁎02 | 6/121 | 4-1⁎01 | 2⁎01 | 3/108 |
a
mAbs with good neutralizing capacity against the 2009 pandemic H1N1 influenza virus.